Log in

NASDAQ:NEONeoGenomics Stock Price, Forecast & News

$26.69
-0.97 (-3.51 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$26.56
Now: $26.69
$27.75
50-Day Range
$25.73
MA: $27.98
$31.02
52-Week Range
$18.52
Now: $26.69
$34.97
Volume1.11 million shs
Average Volume1.02 million shs
Market Capitalization$2.81 billion
P/E Ratio889.96
Dividend YieldN/A
Beta0.79
NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services, which focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Read More
NeoGenomics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.61 out of 5 stars


Industry, Sector and Symbol

Industry Testing laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NEO
CUSIPN/A
Phone239-768-0600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$408.83 million
Cash Flow$0.52 per share
Book Value$4.79 per share

Profitability

Net Income$8.01 million

Miscellaneous

Employees1,700
Market Cap$2.81 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive NEO News and Ratings via Email

Sign-up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter.

NeoGenomics (NASDAQ:NEO) Frequently Asked Questions

How has NeoGenomics' stock been impacted by COVID-19 (Coronavirus)?

NeoGenomics' stock was trading at $24.78 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NEO stock has increased by 7.7% and is now trading at $26.69. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of NeoGenomics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 1 hold rating, 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for NeoGenomics.

When is NeoGenomics' next earnings date?

NeoGenomics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for NeoGenomics.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) released its earnings results on Tuesday, April, 28th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by $0.04. The medical research company had revenue of $106.03 million for the quarter, compared to analyst estimates of $106.03 million. NeoGenomics had a net margin of 0.82% and a return on equity of 2.94%. The firm's quarterly revenue was up 10.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.03) EPS. View NeoGenomics' earnings history.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics updated its first quarter 2020 Pre-Market earnings guidance on Thursday, April, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $106-106 million, compared to the consensus revenue estimate of $104.42 million.

What price target have analysts set for NEO?

9 brokerages have issued 12 month price targets for NeoGenomics' stock. Their forecasts range from $9.00 to $38.00. On average, they expect NeoGenomics' stock price to reach $30.63 in the next twelve months. This suggests a possible upside of 14.7% from the stock's current price. View analysts' price targets for NeoGenomics.

Has NeoGenomics been receiving favorable news coverage?

Media coverage about NEO stock has trended very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. NeoGenomics earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned news articles about the medical research company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news aboutNeoGenomics.

Who are some of NeoGenomics' key competitors?

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology Group (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Micron Technology (MU), Square (SQ), Cisco Systems (CSCO), Inseego (INSG), Advanced Micro Devices (AMD) and Crispr Therapeutics (CRSP).

Who are NeoGenomics' key executives?

NeoGenomics' management team includes the following people:
  • Mr. Douglas M. VanOort, Chairman & CEO (Age 64)
  • Ms. Sharon A. Virag, Chief Financial Officer (Age 52)
  • Dr. Lawrence M. Weiss M.D., Chief Scientific Officer (Age 62)
  • Mr. William Bishop Bonello, Chief Strategy & Corp. Devel. Officer and Director of Investor Relations (Age 54)
  • Mr. George A. Cardoza, Pres of Pharma Services Division (Age 57)

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.57%), Invesco Ltd. (3.67%), State Street Corp (2.86%), Janus Henderson Group PLC (2.65%), Eagle Asset Management Inc. (2.38%) and Geode Capital Management LLC (1.43%). Company insiders that own NeoGenomics stock include Electric Co General, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lynn A Tetrault, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven C Jones and William Bonello. View institutional ownership trends for NeoGenomics.

Which institutional investors are selling NeoGenomics stock?

NEO stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Granahan Investment Management Inc. MA, Ranger Investment Management L.P., BlackRock Inc., Cowen Prime Services LLC, Emerald Mutual Fund Advisers Trust, Russell Investments Group Ltd., and Emerald Advisers LLC. Company insiders that have sold NeoGenomics company stock in the last year include George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven C Jones, and William Bonello. View insider buying and selling activity for NeoGenomics.

Which institutional investors are buying NeoGenomics stock?

NEO stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., Fred Alger Management LLC, Federated Hermes Inc., State Street Corp, Eaton Vance Management, Wells Fargo & Company MN, TCW Group Inc., and Deutsche Bank AG. View insider buying and selling activity for NeoGenomics.

How do I buy shares of NeoGenomics?

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NeoGenomics' stock price today?

One share of NEO stock can currently be purchased for approximately $26.69.

How big of a company is NeoGenomics?

NeoGenomics has a market capitalization of $2.81 billion and generates $408.83 million in revenue each year. The medical research company earns $8.01 million in net income (profit) each year or $0.23 on an earnings per share basis. NeoGenomics employs 1,700 workers across the globe.

What is NeoGenomics' official website?

The official website for NeoGenomics is www.neogenomics.com.

How can I contact NeoGenomics?

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.